Entrada Therapeutics, Inc.TRDANASDAQ

Revenue (LTM)

$25M

-87.9% YoY

Net Income (LTM)

$-144M

-319.0% YoY

Free Cash Flow

$-130M

Revenue CAGR (5Y)

—

Marginsdeclining

FCF($0.1B)

Now unprofitable

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Revenue	0	0	129	211↑63.4%	25↓87.9%
Gross Profit	0	0	129	211↑63.4%	21↓89.9%
Operating Income	-51	-97↓90.2%	-3↑96.7%	47↑1586.7%	-156↓431.8%
Net Income	-51	-95↓84.9%	-7↑92.9%	66↑1081.7%	-144↓319.0%
EBITDA	-50	-95↓90.7%	-0↑99.7%	51↑15920.6%	-142↓380.4%
EPS Diluted	-1.60	-2.79↓74.4%	-0.20↑92.8%	1.68↑940.0%	-3.47↓306.5%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Cash & Equivalents	291	45↓84.5%	68↑49.7%	101↑49.7%	90↓10.7%
Total Current Assets	299	210↓29.7%	370↑76.2%	440↑19.0%	306↓30.4%
Total Assets	306	252↓17.6%	469↑86.1%	526↑12.2%	377↓28.3%
Total Current Liabilities	7	22↑227.0%	159↑622.7%	39↓75.1%	24↓38.1%
Total Liabilities	7	40↑455.2%	227↑474.2%	98↓57.0%	71↓27.0%
Total Equity	299	213↓28.8%	242↑14.0%	429↑76.9%	306↓28.6%
Total Debt	0	26	68↑163.1%	59↓13.2%	51↓14.0%
Net Debt	-291	-19↑93.4%	1↑103.3%	-42↓6788.5%	-39↑6.1%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Operating Cash Flow	-51	-94↓84.4%	140↑249.1%	-42↓129.7%	-129↓209.2%
Capital Expenditure	-5	-3↑37.0%	-6↓94.5%	-3↑43.7%	-1↑67.0%
Free Cash Flow	-55	-97↓74.4%	134↑238.8%	-45↓133.3%	-130↓189.7%
Stock-Based Comp	3	10↑291.7%	13↑32.5%	18↑36.6%	20↑9.5%
Net Change in Cash	252	-246↓197.6%	22↑109.1%	34↑49.7%	-11↓132.2%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance